Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Biologic approval (1)
- Biologics (1)
- Biologics License Application (1)
- Biologics Price Competition and Innovation Act (1)
- Biopharmaceuticals (1)
-
- Biosimilar (1)
- Biosimilars (1)
- Committee for Medicinal Products for Human Use (1)
- European Medicines Agency (1)
- European Union (1)
- Food and Drug Administration (1)
- Hatch-Waxman Act (1)
- INN (1)
- International Nonproprietary name (1)
- Naming (1)
- Nomenclature (1)
- Nonproprietary Naming of Biological Products (1)
- Pharmaceuticals (1)
- Public Health Services Act (1)
- Regulatory Approval (1)
- World Health Organization (1)
- Publication Type
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Boundary Work In Environmental Law, Gregg P. Macey
Boundary Work In Environmental Law, Gregg P. Macey
Faculty Scholarship
No abstract provided.
Biosimilar Naming: A Call For Uniformity In A Complex Field, Jacqueline Genovese
Biosimilar Naming: A Call For Uniformity In A Complex Field, Jacqueline Genovese
Brooklyn Journal of International Law
Recombinant technology has opened a pathway for a means of producing a variety of therapeutic proteins and generating the growth of the biopharmaceutical industry. Further, due the patent expirations of a number of biologics in the coming years, there has been an increased interest in the development of generic biologics, also known as biosimilars, and a widespread push for biosimilar FDA approval in the United States. While the pressure for the expansion of biosimilar approval is warranted, the FDA must be cautious when implementing regulatory guidelines. Since biologics differ greatly from small-molecule drugs, biologics have a distinct approval process. The …